Register Now
Live Webinar: Phenotyping Midbrain Organoids and Dopaminergic Neurons for Studying Parkinson’s Disease and Therapeutic Discovery
Join our live webinar to discover methods for imaging and single-cell phenotyping 2D and 3D models.
Induced pluripotent stem cell (iPSC)-derived neural models enable researchers to work with and visualize living human neuronal tissue that closely resembles cells from distinct regions of the human brain. In this webinar, Dr. Thomas Durcan will outline how midbrain organoids and dopaminergic (DOPA) neurons can be combined with automated high-content imaging and single-cell flow cytometry workflows to profile cells within these 2D and 3D structures at the single-cell level. He will describe the growth and development of these models over time, and explain how single-cell phenotyping provides a better understanding of the complexities and cell compositions within these brain tissues. By combining these advanced technologies, researchers can gain a better understanding of Parkinson’s disease and leverage organoids to evaluate novel therapeutic approaches.
Phenotyping Midbrain Organoids and Dopaminergic Neurons for Studying Parkinson’s Disease and Therapeutic Discovery
Date: Wednesday, February 12, 2025
Time: 8:00 a.m. PST | 11:00 a.m. EST | 4:00 p.m. GMT | 5:00 p.m. CET
If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.
What You’ll Learn:
- Obtain an overview of brain organoid models with an emphasis on midbrain organoid generation.
- Learn about the development of iPSC-derived DOPA neurons.
- Learn about an innovative flow cytometry-based workflow for the detailed characterization of midbrain organoids and DOPA neurons.
- Discover methods for imaging and single-cell phenotyping 2D and 3D models.
Associate Professor, Montreal Neurological Institute (The Neuro) and McGill University
Dr. Thomas M. Durcan is an Associate Professor at the Montreal Neurological Institute (The Neuro) and McGill University. He is also the Director of the Neuro’s Early Drug Discovery Unit (EDDU). His work focuses on leveraging human induced pluripotent stem cells (iPSCs) for fundamental and translational research through collaborations with academic and industry partners. Founded less than a decade ago, the EDDU has developed a cohort of 200+ iPSCs, advancing them into various projects and generating a wide range of neuronal and glial subtypes, as well as more advanced 3D brain organoid models. Their research focuses on Parkinson’s disease, ALS, and neurodevelopmental disorders, supported by grants from the Michael J. Fox Foundation, Brain Canada, CQDM, the Canadian Institutes of Health Research, the U.S. Department of Defense (DOD), and the McGill Healthy Brains, Healthy Lives (HBHL) initiative.
